Breaking News, Collaborations & Alliances

BiOneCure, Nanjing Leads Biolabs Partner to Develop ADCs for Solid Tumors

Collaboration expected to expand innovative R&D capabilities of both companies.

BiOneCure Therapeutics, Inc. entered into a strategic collaboration with Nanjing Leads Biolabs to develop a range of innovative anti-drug conjugates (ADCs) for treating solid tumors. BiOneCure is a clinical-stage biopharmaceutical company dedicated to developing next-generation ADCs, while Leads Biolabs is a clinical-stage biotech focused on the research, development, and commercialization of next-generation tumor immunotherapy antibody drugs. BiOneCure has developed several ADC payload-li...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters